Olmesartan medoxomil

Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC₅₀ of 66.2 μM.Inhibition of Arachidonic acid (AA) metabolism by angiotensin II receptor blockers (ARBs) is detected in a concentration-dependent manner with IC₅₀ of Olmesartan (66.2 μM). Olmesartan medoxomil (OLM) is a potent and selective angiotensin AT1 receptor blocker.The efficacy of Olmesartan (20 mg/kg) studied in db/db diabetic mice for a period of 12 weeks starting from week 10 to 12 of age. The db/db mice have 11.7 fold increased albuminuria in comparison to control mice at week 22 to 24 of age. Twelve weeks Olmesartan administration significantly reduces albuminuria in db/db mice by 77% as compared with placebo treated db/db mice. The albumin/creatinine ratio (ACR) is increased in db/db mice in comparison to control mice by 7.1 fold and Olmesartan treatment significantly decreases ACR by 59% in db/db mice.

RAAS Inhibitors Related Prodcuts:

Azilsartan; VTP-27999 TFA; Eprosartan Mesylate; Telmisartan; Valsartan; Enalapril Maleate; Temocapril hydrochloride; Sparsentan; Fimasartan; Fosinopril Sodium

[1]. Nam HJ, et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. Cancer Lett. 2011 Mar 28;302(2):155-65.

[2]. Cha MY, et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.

[3]. Kang MH, et al. Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. Cancer Res Treat. 2015 Mar 5.